Rheumatology Research Group, Vall d'Hebron Research Institute, Vall Hebron University Hospital, Pg Vall Hebron 119-120, 08035, Barcelona, Spain.
Rheumatology Department, Hospital Clínic de Barcelona i IDIBAPS, Barcelona, Spain.
Arthritis Res Ther. 2020 Aug 25;22(1):196. doi: 10.1186/s13075-020-02287-9.
The mechanisms by which only some rheumatoid arthritis (RA) patients respond favorably to TNF blockade are still poorly characterized. The goal of this study was to identify biological features that explain this differential response using a multilevel transcriptome analysis of the synovial membrane.
Synovial samples from 11 patients on anti-TNF therapy were obtained by arthroscopy at baseline and week 20. Analysis of the synovial transcriptome was performed at the gene, pathway, and cell-type levels. Newly characterized pathogenic cell types in RA, peripheral helper T cells (T), and CD34-THY1+ fibroblasts were estimated using a cell-type deconvolution approach. T association was validated using immunofluorescence. External validation was performed on an independent dataset.
After multiple-test correction, 16 and 4 genes were differentially expressed at baseline and week 20, respectively. At the pathway level, 86 and 17 biological processes were significantly enriched at baseline and week 20, respectively. Longitudinal expression changes were associated with a drastic decrease of innate immune activity (P < 5e-30), and an activation of the bone and cartilage regeneration processes (P < 5e-10). Cell-type deconvolution revealed a significant association between low T cells at baseline and a better response (P = 0.026). Lower T cells were maintained in good responders up to week 20 (P = 0.032). Immunofluorescent analyses confirmed the accuracy of the cell-type estimation (r = 0.58, P = 0.005) and an association with response. T association with anti-TNF response was validated in an independent sample of RA patients (P = 0.0040).
A lower abundance in the synovial membrane of the pathogenic T cell type newly associated with RA, peripheral helper T lymphocyte, is associated with a good response to anti-TNF therapy. Major changes in the myeloid cell compartment were also observed in response to therapy. The results of this study could help develop more effective therapies aimed at treating the pathogenic mechanisms in RA that are currently not well targeted by anti-TNF agents.
目前仍不清楚为何只有部分类风湿关节炎(RA)患者对 TNF 阻滞剂治疗有良好反应。本研究的目的是通过对滑膜的多层次转录组分析,确定能够解释这种差异反应的生物学特征。
通过关节镜在基线和第 20 周时采集 11 名接受抗 TNF 治疗的患者的滑膜样本。在基因、途径和细胞类型水平上分析滑膜转录组。使用细胞类型去卷积方法估计 RA 中新鉴定的致病细胞类型,外周辅助性 T 细胞(T 细胞)和 CD34-THY1+成纤维细胞。使用免疫荧光法验证 T 细胞相关性。在独立数据集上进行外部验证。
经多次检验校正后,分别有 16 个和 4 个基因在基线和第 20 周时差异表达。在途径水平上,分别有 86 个和 17 个生物学过程在基线和第 20 周时显著富集。纵向表达变化与固有免疫活性的显著降低(P < 5e-30)和骨与软骨再生过程的激活有关(P < 5e-10)。细胞类型去卷积显示,基线时 T 细胞数量较低与更好的反应相关(P = 0.026)。在良好反应者中,T 细胞数量一直维持到第 20 周(P = 0.032)。免疫荧光分析证实了细胞类型估计的准确性(r = 0.58,P = 0.005)及其与反应的相关性。在另一批 RA 患者的样本中验证了 T 细胞与抗 TNF 反应的相关性(P = 0.0040)。
与新鉴定的与 RA 相关的致病性 T 细胞(外周辅助性 T 细胞)在滑膜中的丰度较低与抗 TNF 治疗的良好反应相关。治疗后骨髓细胞群也发生了重大变化。本研究结果可能有助于开发更有效的治疗方法,针对目前抗 TNF 药物治疗效果不佳的 RA 致病机制。